Wells Fargo
CDAK

Wells Fargo’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Wells Fargo’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-332
Closed -$58 – 7808
2023
Q1 		$58 Buy
332
+169
+104% +$94 ﹤0.01% 7077
2022
Q4 		$65 Sell
163
-285
-64% -$188 ﹤0.01% 6924
2022
Q3 		$0 Sell
448
-9
-2% -$19 ﹤0.01% 7767
2022
Q2 		$1K Sell
457
-5,398
-92% -$19K ﹤0.01% 6694
2022
Q1 		$37K Sell
5,855
-5,383
-48% -$33.8K ﹤0.01% 5794
2021
Q4 		$125K Sell
11,238
-1,400
-11% -$19.4K ﹤0.01% 5520
2021
Q3 		$207K Buy
12,638
+12,288
+3,511% +$220K ﹤0.01% 5080
2021
Q2 		$6K Sell
350
-1,677
-83% -$32.2K ﹤0.01% 6309
2021
Q1 		$31K Sell
2,027
-863
-30% -$18.8K ﹤0.01% 6025
2020
Q4 		$93K Buy
+2,890
New +$38.2K ﹤0.01% 5391

Wells Fargo's CDAK Position: Q2 2023 in Review

Wells Fargo sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 332 shares — an estimated $58 sold.

Wells Fargo first reported a position in CDAK in Q4 2020 and held it in 10 quarters. The position peaked at $207K in Q3 2021. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

  • Wells Fargo reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Wells Fargo sold 332 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $58.
  • Wells Fargo first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • Wells Fargo's Codiak BioSciences, Inc. Common Stock position peaked at $207K in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.